GlaxoSmithKline Pharmaceuticals Ltd. (GSK India) announced its financial results for the second quarter ended September 30, 2025. The company’s EBIDTA margins for the quarter grew by 250 bps. Revenue from Operations was INR 974 Crores and Profit After Tax (PAT) was INR 255 Crores. The company’s Oncology portfolio is off to a strong start with therapies Jemperli (Dostarlimab) and Zejula (Niraparib) being well-received.
Financial Performance Highlights
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced its financial results for the second quarter of FY26, which ended on September 30, 2025. The company has demonstrated strong profitability with sustained leadership in anti-infectives, dermatology and vaccines.
Key Financial Metrics
During the quarter:
Revenue from Operations: INR 974 Crores
Profit After Tax (PAT): INR 255 Crores
EBIDTA margins for the quarter stood at 34.4%, reflecting a growth of 250 bps, driven by improved gross margins and operating leverage.
Business Segment Performance
The General Medicines portfolio delivered competitive performance, with key promoted brands achieving market share gains. The Vaccines business saw market share expansion, driven by strong demand and continued leadership in the self-pay private market for Paediatric vaccines. The Adult vaccines business continues to see strong traction, led by the growing adoption of Shingrix.
Oncology Portfolio
GSK’s entry into Oncology with the launch of its specialised therapies Jemperli (Dostarlimab) and Zejula (Niraparib) have been well-received by Healthcare Professionals (HCPs). These assets reinforce the Company’s commitment to bridging critical gaps in specialised cancer care in India.
Management Commentary
Bhushan Akshikar, Managing Director, GSK India, said: “Within two months of launch, our Oncology portfolio is impacting patients by addressing a critical unmet need in gynaecological cancers in India. Together, these assets represent meaningful progress in women’s cancer care. Moving ahead, we remain focused on ensuring that cutting-edge innovative treatments are both available and accessible to those who need them the most, supported by our comprehensive patient support and financing initiatives.”
Product Information
Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer.
Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer.
Source: BSE
